Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson maintains a Buy rating on Biofrontera (NASDAQ:BFRI) but lowers the price target from $140 to $18.
July 05, 2023 | 11:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biofrontera's price target has been significantly reduced from $140 to $18 by Benchmark, although the Buy rating is maintained.
The drastic reduction in Biofrontera's price target by Benchmark, despite maintaining a Buy rating, could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100